Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2022 / Cilt: 56 - Sayı: 1

Secukinumab

Sekukinumab

Pages
52–54
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has a safe side effect profile in terms of latent tuberculosis activation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A.
📊
Key Findings & Data:In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks.
💡
Conclusion & Impact:It has a safe side effect profile in terms of latent tuberculosis activation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks. As well as in chronic plaque psoriasis, secukinumab has also been found effective and safe as monotherapy in nail and hairy skin psoriasis and psoriatic arthritis. Secukinumab should be used with caution in patients or their first-degree relatives who have inflammatory bowel disease. It has a safe side effect profile in terms of latent tuberculosis activation

Özet

Sekukinumab interlökin-17A’ya yönelik, insan kaynaklı immünoglobulin G1/κ tipinde bir monoklonal antikordur. Klinik araştırmalarda PAŞİ75 yanıtı elde edilen hasta oranı 12. haftada %77 ile 81 arasında değişmektedir. Kronik plak tip psoriasis yanı sıra tırnak ve saçlı deri psoriasisi ile psoriatik artritte de tek başına etkili ve güvenli bulunmuştur. Kendisinde ya da birinci derece yakınlarında inflamatuar barsak hastalığı bulunanlarda dikkatli kullanım gerektiren sekukinumab, latent tüberküloz aktivasyonu açısından güvenli bir yan etki profiline sahiptir

🔖

Cite This Article

ATAKAN, N. (2022). Secukinumab. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 52–54. https://ajindex.com/articles/622441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lynde CW, Poulin Y, Vender R, et al.: Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. JAAD 2014;71:141-50
  2. Cosentyx [prescribinginformation]. East Hanover, NJ: Novartis Pharmaceutical Corp; June 2020
  3. Verxant (Sekukinumab) Sağlık Bakanlığı onaylı kısa ürün bilgisi 28.5.2019
  4. Langley RG, Elewski BE, Lebwohl M, et al.: Secukinumab in plaquepsoriasis - results of twophase 3 trials. N Engl J Med 2014;371:326-38
  5. Thaçi D, Blauvelt A, Reich K, et al.: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderateto severe plaquepsoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73:400-9
  6. Reich K, Sullivan J, Arenberger P, et al.: Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled Transfigure trial. Br J Dermatol 2019;181:954-66
  7. Gottlieb A, Sullivan J, vanDoorn M, et al.: Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol 2017;76:70-80
  8. Kircik L, Fowler J, Weiss J, et al.: Efficacy of secukinumab for moderate-tosevere head and neck psoriasis over 52 weeks: pooledanalysis of fourphase 3 studies. Dermatol Ther (Heidelb) 2016;6:627-38
  9. Gottlieb AB, Langley RG, Philipp S, et al.: Secukinumab improves physical function in subjects with plaque psoriasis & psoriaticarthritis: results from two randomized, phase 3 trials. J Drugs Dermatol 2015;14:821-33
  10. Weng HJ, Wang TS, Tsai TF: Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol 2018;178:1439-40
  11. Mugheddu C, Atzori L, Lappi A, et al.: Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol 2017;31:e420-1
  12. Reich K, Blauvelt A, Armstrong A, et al.: Secukinumab, a fullyhuman antiinterleukin- 17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2017;176:752-8
  13. Ohtsuki M, Morita A, Abe M, et al.: Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: sub analysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014;41:1039-46
  14. Kammüller M, Tsai TF, Griffiths CEM, et al.: Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin T